Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- GLP-1 receptor agonists work best with dosing protocols tailored to your labs, symptoms, and long-term metabolic goals.
- Titration schedules for semaglutide, tirzepatide, compounded GLP-1, and GLP-3R change over time based on response, side effects, and lab monitoring.
- Compounded formulations require exact volume calculations and close practitioner oversight to prevent dosing mistakes and protect safety.
- Maintenance dosing focuses on holding results with the lowest effective dose, with check-ins every 8–12 weeks.1
- Patients who want a personalized GLP-1 or GLP-3R plan can book a consultation at Mirror Plastic Surgery with Ellie Pranckevicius, FNP-BC.
Core GLP-1 Terms You Will See Throughout This Guide
GLP-1 receptor agonists are peptide-based medications that mimic glucagon-like peptide-1, a hormone released in the gut after eating. They slow gastric emptying, reduce appetite, and improve insulin sensitivity. Semaglutide and tirzepatide are the most widely studied agents in this class, available as FDA-approved branded pens (Ozempic, Wegovy, Mounjaro, Zepbound) and as compounded formulations prepared by licensed compounding pharmacies.
Titration refers to the gradual escalation of dose over a defined schedule, typically measured in weeks, to allow the body to adapt and to reduce gastrointestinal side effects such as nausea, vomiting, and diarrhea. Once the body has adapted and the target therapeutic effect is reached, the patient moves into maintenance dosing, which is the stable dose that sustains metabolic benefit without further escalation.
Compounded GLP-1 formulations differ from branded pens in concentration and delivery format. Compounded vials are measured in milligrams per milliliter (mg/mL), so the patient or clinician must calculate the volume drawn into an insulin syringe. Branded pens deliver a fixed dose per click. Because concentrations vary by pharmacy, unit-to-mg conversions must be calculated for each compounded vial, and a practitioner should verify these calculations to avoid dosing errors.
GLP-3R is a newer-generation formulation that targets additional receptor pathways beyond the classical GLP-1 receptor. Early data suggest advantages in gastrointestinal tolerability and muscle preservation compared to earlier GLP-1 agents.1
Ellie’s Background and Approach to GLP-1 Therapy
Peptide and GLP-1 protocols at Mirror Plastic Surgery are led by Ellie Pranckevicius, FNP-BC, a board-certified Family Nurse Practitioner who earned her Bachelor’s in Health Science from Boston University and her Bachelor’s and Master’s in Nursing from the University of South Florida. She spent four years in the Neuroscience ICU at Tampa General Hospital, where she developed advanced skills in metabolic physiology, lab interpretation, and complex patient management. She combines that critical-care foundation with formal esthetician training and aesthetic medicine experience, which gives her both clinical and aesthetic insight when designing peptide protocols.
Schedule a consultation with Ellie to receive a GLP-1 protocol that reflects your specific lab profile and goals.
What a Supervised GLP-1 Plan Looks Like Day to Day
A supervised GLP-1 protocol at Mirror Plastic Surgery starts with a comprehensive consultation and review of lab panels, including thyroid, liver, kidney, diabetes markers, and hormone levels. These results establish a baseline and identify any contraindications before the first dose. From that baseline data, Ellie maps the full treatment arc from starting dose through each escalation checkpoint to the target maintenance phase. Patients receive detailed reconstitution and self-administration instructions, often with video demonstrations, so they feel confident with each injection. Follow-up happens through direct text access and scheduled telemedicine visits, and lab markers are reassessed at set intervals to guide dose changes or maintenance.
Standard Dosing Protocol for Semaglutide
The standard titration schedule for semaglutide (Wegovy) for chronic weight management follows a stepwise weekly injection protocol. The general structure is as follows:
| Weeks | Weekly Dose (mg) | Notes |
|---|---|---|
| 1–4 | 0.25 mg | Initiation dose, not a therapeutic dose |
| 5–8 | 0.5 mg | First escalation |
| 9–12 | 1.0 mg | Second escalation |
| 13–16 | 1.7 mg | Third escalation |
| 17+ | 2.4 mg | Target maintenance dose |
Compounded semaglutide follows the same mg-based escalation logic but requires volume calculation based on the vial’s specific concentration. Patients who experience significant GI side effects at any step may hold at the current dose for an additional four weeks before escalating, in consultation with their practitioner. Knowing when to pause at a dose and when to move up depends on clear clinical criteria, which are outlined in the next section.
When to Increase GLP-1 Dose for Weight Loss
Dose escalation is appropriate when a patient has tolerated the current dose for the full prescribed interval, usually four weeks. Escalation also requires that GI side effects have resolved or are minimal and that weight loss has slowed to less than 0.5–1% of body weight per month. Escalation is deferred when nausea, vomiting, or diarrhea remain active, when the patient has recently started a new medication that may interact, or when lab markers suggest hepatic or renal stress. The decision to escalate is based on symptoms, lab trends, and patient-reported outcomes rather than on the calendar alone. Patients supervised by Ellie receive written instructions that spell out when to contact her before changing any dose.
GLP-1 Dosing Ranges for Common Agents
The table below compares the general dosing ranges for the four primary agents used in supervised protocols. Compounded formulations are listed as mg-equivalent ranges because concentration per vial varies by pharmacy, so volume in units on an insulin syringe must be calculated for each vial. All figures reflect published prescribing information or standard compounding practice ranges and still require practitioner verification for each patient.
| Agent | Starting Dose | Target/Max Dose | Frequency |
|---|---|---|---|
| Semaglutide (Wegovy) | 0.25 mg | 2.4 mg | Weekly |
| Tirzepatide (Zepbound) | 2.5 mg | 15 mg | Weekly |
| Compounded GLP-1 (semaglutide base) | 0.25 mg equivalent | 2.4 mg equivalent | Weekly, volume per vial concentration |
| GLP-3R (compounded) | Practitioner-determined | Practitioner-determined | Weekly, protocol individualized |
Because GLP-3R is a compounded formulation without a single standardized concentration, dosing is set for each patient during consultation and cannot be summarized in a fixed-unit chart.
How to Calculate Your Semaglutide Volume
For compounded semaglutide vials, the injection volume in milliliters is calculated with the formula Volume (mL) = Prescribed dose (mg) ÷ Vial concentration (mg/mL). On a standard U-100 insulin syringe, 1 mL equals 100 units. For example, if a vial is prepared at 5 mg/mL and the prescribed dose is 0.25 mg, the volume is 0.05 mL, which equals 5 units on a U-100 syringe. Vial concentrations from compounding pharmacies commonly range from 1 mg/mL to 10 mg/mL, so guessing or calculating alone can easily cause dosing errors. Mirror Plastic Surgery provides written dose cards and video walkthroughs that match the exact vial a patient receives.
GLP-3R Dosing and Transition Protocols
GLP-3R compounds target receptor pathways linked to improved insulin sensitivity, reduced cardiovascular risk factors, and lower rates of muscle loss compared to first-generation GLP-1 agents. Because GLP-3R is compounded, there is no single FDA-approved titration schedule. Protocols are built around baseline metabolic labs, body composition, and any prior GLP-1 exposure. Most patients start with a conservative dose and wait four weeks between escalations, similar to semaglutide, with adjustments for the agent’s distinct receptor activity. Patients moving from semaglutide or tirzepatide to GLP-3R usually complete a washout or cross-titration period that their practitioner defines.
GLP-1 Maintenance Dose and Long-Term Planning
Maintenance dosing is the phase in which a patient has reached a target weight or metabolic goal and the focus shifts from active loss to preserving results. For semaglutide, the approved maintenance dose is 2.4 mg weekly, although some patients maintain results at lower doses of 1.0–1.7 mg with fewer side effects. Maintenance is a moving target rather than a fixed endpoint, so lab markers, weight trends, energy, and appetite are reassessed every 8–12 weeks to decide whether the dose should change. Discontinuing GLP-1 therapy without a tapering or transition plan typically results in weight regain because the underlying metabolic drivers remain.1
Connect with Ellie to review whether it is time to shift from active titration to a maintenance strategy.
What to Do If You Miss a Dose
The standard missed-dose rule for weekly semaglutide is to administer the dose as soon as possible if fewer than five days have passed and at least 48 hours remain before the next scheduled dose. If more time has passed, the patient skips the missed dose and resumes the regular weekly schedule. Patients should not double-dose under any circumstance. For tirzepatide, a four-day missed-dose rule applies per prescribing information. For compounded GLP-1 or GLP-3R, patients should follow the written instructions from their practitioner, since protocols can differ. Patients supervised by Ellie are encouraged to text her directly if they are unsure how to handle a missed dose.
Injection Technique and Safe Storage
GLP-1 injections are given subcutaneously, usually in the abdomen, upper thigh, or upper arm, with rotation of sites each week to reduce the risk of lipohypertrophy. Compounded vials are stored in the refrigerator at 36–46°F (2–8°C) and should not be frozen or exposed to direct light. Branded pens follow the storage instructions on the manufacturer label. Needles of 4–6 mm length work for most patients. Reconstituted compounded vials are typically stable for 28–30 days in the refrigerator, and patients should confirm exact stability windows with the dispensing pharmacy.
Current Landscape for GLP-1 and GLP-3R Therapies
Compounded GLP-1 use expanded significantly between 2023 and 2025 as demand for semaglutide and tirzepatide exceeded branded supply. Compounding pharmacies operating under 503A and 503B designations filled this gap by producing patient-specific and batch formulations. Regulatory scrutiny of compounded GLP-1 products has increased, and the FDA has issued guidance on when compounding remains permissible. GLP-3R formulations now represent a newer frontier, with early clinical and real-world data suggesting improved GI tolerability and a more favorable muscle-preservation profile compared to GLP-1 alone. Supervised protocols that rely on lab data and ongoing follow-up are increasingly viewed as the standard that separates consistent therapeutic outcomes from the unpredictable results seen with unsupervised online sourcing.1
Important Safety and Eligibility Considerations
GLP-1 and GLP-3R therapies are not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. For candidates who clear this screening, baseline and follow-up labs, including HbA1c, fasting glucose, lipid panel, liver enzymes, and kidney function, are essential for safe prescribing and dose management. These labs matter because results vary widely between individuals based on genetics, baseline metabolic health, dietary adherence, and activity level. Timelines to meaningful weight loss usually range from 8 to 20 weeks, depending on the agent, dose, and individual response.1 Sourcing from unverified online suppliers introduces risks of incorrect concentration, contamination, and lack of clinical follow-up, all of which supervised care is designed to avoid.
Risks, Limitations, and Common Challenges
The most common adverse effects of GLP-1 therapy are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These symptoms tend to peak during dose escalation and often lessen with time. Muscle mass loss is a known concern with rapid weight loss on GLP-1 agents, so resistance training and adequate protein intake of 1.2–1.6 g/kg body weight are standard recommendations. Pancreatitis is a rare but serious risk, and patients with a history of pancreatitis are generally not candidates. Unsupervised use increases all of these risks by removing clinical checkpoints such as lab monitoring, symptom review, and dose adjustment that allow early detection and management of adverse events.
Common Misconceptions About GLP-1 and GLP-3R
One-size-fits-all dosing produces equivalent outcomes. Individual variation in GLP-1 receptor sensitivity, gastric motility, and metabolic baseline means that the same dose can produce very different results across patients.1 Protocols work better when they are calibrated to the individual.
A higher dose always produces faster or better results. Escalating beyond a patient’s tolerability threshold increases side effects without proportional benefit and can lead to stopping therapy. The optimal dose is the lowest dose that delivers the desired effect.
GLP-1 and GLP-3R peptides are only for weight loss. These agents also improve insulin sensitivity, reduce cardiovascular risk markers, and show emerging benefits in non-alcoholic fatty liver disease and inflammation, which matter even when weight change is modest.
FAQ
How long does it take to reach the maintenance dose on semaglutide?
Following the standard titration schedule, most patients reach the 2.4 mg maintenance dose after about 16–17 weeks. Patients who experience significant GI side effects may hold at an intermediate dose for an additional four weeks before escalating, which lengthens the titration period. The priority is tolerability and adherence rather than reaching maintenance as quickly as possible.
Can I use compounded semaglutide if branded pens are available?
Compounded semaglutide may be appropriate when branded formulations are unavailable because of supply issues, when a patient needs a dose or concentration that a branded pen does not offer, or when cost blocks access. The decision depends on a clinical review of the compounding pharmacy’s quality standards, including batch testing documentation. Mirror Plastic Surgery uses compounded peptides only from pharmacies with verified quality and purity testing.
What labs are required before starting a GLP-1 protocol?
A standard pre-treatment panel includes fasting glucose, HbA1c, a comprehensive metabolic panel for liver and kidney function, a lipid panel, thyroid function with TSH, and a hormone panel when relevant. These results identify contraindications, set metabolic baselines, and help Ellie choose the starting dose and titration pace. If a patient does not have recent labs, they are ordered as part of the consultation.
What happens if I stop GLP-1 therapy after reaching my goal weight?
As noted in the maintenance section, stopping therapy abruptly usually leads to gradual weight regain over weeks to months as the drug’s appetite-suppressing and metabolic effects fade. Some patients move to a lower maintenance dose or a less frequent injection schedule instead of stopping completely. Others shift to complementary protocols, such as GLP-3R or peptides that support metabolic health, to help maintain results. This decision is made together with the practitioner based on labs and patient goals.
Is GLP-3R appropriate for someone who has already tried semaglutide or tirzepatide?
GLP-3R may be a good option for patients who had significant GI side effects on first-generation GLP-1 agents, who are focused on preserving muscle, or who reached only partial metabolic goals on semaglutide or tirzepatide. A clinical assessment that includes current labs and a review of prior therapy response is required before transitioning. GLP-3R functions as a distinct formulation with a different receptor profile rather than as a direct one-to-one substitute for branded agents.
Why Supervised GLP-1 Protocols Deliver More Reliable Results
GLP-1 and GLP-3R dosing protocols work poorly as generic templates. Effective and safe therapy depends on titration that reflects baseline labs, ongoing clinical monitoring, and a practitioner with the expertise to adjust protocols as response changes. The gap between supervised and unsupervised GLP-1 use is substantial, because a supervised plan is calibrated to your physiology instead of following a generic schedule without context.
Mirror Plastic Surgery offers concierge-level GLP-1 and GLP-3R protocols for patients in the Tampa and St. Petersburg area and for remote patients across the United States. Every protocol is designed by Ellie Pranckevicius, FNP-BC, and supported by direct, ongoing access throughout treatment.
Book your initial appointment to begin a GLP-1 or GLP-3R protocol aligned with your metabolic health goals.
Disclaimer: GLP-1 receptor agonists and GLP-3R compounded formulations are subject to federal and state prescribing regulations. Compounded peptides are not FDA-approved drug products. All protocols described in this article require evaluation and supervision by a licensed healthcare practitioner. This content is intended for educational purposes only and does not constitute medical advice. Individual outcomes vary. Last updated June 2026.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
